bioAffinity Technologies (BIAF) Liabilities and Shareholders Equity (2021 - 2026)
bioAffinity Technologies has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $7.9 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 43.23% to $7.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35.2 million through Mar 2026, up 39.31% year-over-year, with the annual reading at $11.0 million for FY2025, 68.27% up from the prior year.
- Liabilities and Shareholders Equity was $7.9 million for Q1 2026 at bioAffinity Technologies, down from $11.0 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $14.1 million in Q3 2022 and troughed at $4.8 million in Q2 2025.
- The 5-year median for Liabilities and Shareholders Equity is $8.2 million (2023), against an average of $8.8 million.
- Year-over-year, Liabilities and Shareholders Equity skyrocketed 738.23% in 2022 and then plummeted 35.7% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $12.2 million in 2022, then crashed by 32.51% to $8.2 million in 2023, then dropped by 20.77% to $6.5 million in 2024, then surged by 68.27% to $11.0 million in 2025, then decreased by 27.51% to $7.9 million in 2026.
- Per Business Quant, the three most recent readings for BIAF's Liabilities and Shareholders Equity are $7.9 million (Q1 2026), $11.0 million (Q4 2025), and $11.5 million (Q3 2025).